- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05091801
Particle Size Project (EPSOM)
April 12, 2022 updated by: Duke University
Effects of Increased Chewing Efficiency on the Gut Microbiome
This study is designed to test the effects of chewing efficiency on human gut microbiome composition and function.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Our working hypothesis is that increased chewing will lead to an increase in short-chain fatty acid production We further expect this effect to lead to a detectable decrease in fecal particle size and distinct changes in gut microbial community composition.
Here, we will explore this hypothesis using a fixed-order within-subjects study design in a group of healthy participants.
Each participant will have one week of normal dietary habits and one week of increased chewing time.
We will collect stool samples three times per week in order to measure microbial abundance and metabolism.
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27708
- Duke University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Above age 18?
- Able to provide stool samples at no risk to yourself?
- Do you have card access to the CIEMAS building (work in CIEMAS, in Pratt School, or undergraduate at Duke), and are you able to visit this building (at times of your own convenience) for the purposes of this study?
Exclusion Criteria:
- Oral antibiotic treatment within the past month?
- Have a history or current diagnosis of irritable bowel syndrome?
- Have a history or current diagnosis of inflammatory bowel disease?
- Have a history or current diagnosis of type 2 diabetes?
- Have a history or current diagnosis of chronic kidney disease with decreased kidney function?
- Have a history or current diagnosis of intestinal obstruction?
- Have a history or current diagnosis of untreated colorectal cancer?
- Have you had a colonoscopy within the past month?
- Had oral antibiotics within the past month?
- Do you consume one entire non-snack meal or more per week in liquid form (smoothie, meal replacement drink, etc.)?
- Do you have any dental issues or other physical limitations that would prevent you from thoroughly chewing your food?
- Do you currently practice any mindfulness or dietary techniques that involve making sure that your food is chewed thoroughly?
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control + Intervention
We will explore our hypothesis using a fixed-order within-subjects study design in a group of healthy participants.
Each participant will have one week of normal dietary habits and one week of increased chewing time.
We will collect stool samples three times per week in order to measure microbial abundance and metabolism.
|
Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Change in short-chain fatty acid (SCFA) measured in stool samples by gas chromatography
Time Frame: 1 week baseline and 1 week intervention
|
1 week baseline and 1 week intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in median fecal particle size as measured by laser diffraction
Time Frame: 1 week baseline and 1 week intervention
|
1 week baseline and 1 week intervention
|
Change in gut microbiome composition as measured by 16S rRNA-encoding gene amplicon sequence analysis
Time Frame: 1 week baseline and 1 week intervention
|
1 week baseline and 1 week intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lawrence David, Duke University - MGM
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 26, 2021
Primary Completion (Actual)
April 1, 2022
Study Completion (Actual)
April 1, 2022
Study Registration Dates
First Submitted
October 13, 2021
First Submitted That Met QC Criteria
October 13, 2021
First Posted (Actual)
October 25, 2021
Study Record Updates
Last Update Posted (Actual)
April 14, 2022
Last Update Submitted That Met QC Criteria
April 12, 2022
Last Verified
September 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- Pro00108805
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intervention
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of FloridaCompletedSensitivityUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHuman Papillomavirus InfectionUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Cancer Society, Inc.Completed
-
Vanderbilt UniversityAgency for Healthcare Research and Quality (AHRQ)Completed